AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36084153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional sodium stibogluconate (SSG)
Number of subjects: 83
Study 33350325 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebeverine 135 mg 3 times a day for 3 months
Number of subjects: 99
Study 33350325 — intervention group
Group type: COMPARATOR
Intervention: Placebo 3 times a day for 3 months
Number of subjects: 99
Study 35101099 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter induction schedule of prednisolone (3 weeks)
Number of subjects: 0
Study 35101099 — intervention group
Group type: COMPARATOR
Intervention: Standard induction schedule of prednisolone (5 weeks)
Number of subjects: 0
Study 35101099 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting doxorubicin with mitoxantrone in delayed intensification
Number of subjects: 0
Study 35101099 — intervention group
Group type: COMPARATOR
Intervention: Standard doxorubicin in delayed intensification
Number of subjects: 0
Study 35101099 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall event-free survival
Number of subjects: 0
Study 35101099 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-free survival by risk groups
Number of subjects: 0
Study 35101099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis rates in induction phase
Number of subjects: 0
Study 34019470 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention group (T group)
Number of subjects: 800
Study 34019470 — intervention group
Group type: EXPERIMENTAL
Intervention: Written notification intervention group (W group)
Number of subjects: 800
Study 34019470 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 800
Study 33090616 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Counselors (GCs)
Number of subjects: 652
Study 33090616 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recommendations (comprehensive, check back, wrong)
Number of subjects: 652
Study 33090616 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrong recommendation
Number of subjects: 652
Study 33090616 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct active recommendations
Number of subjects: 652
Study 33712356 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 110
Study 33712356 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 33712356 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 110
Study 34582720 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg NEEM
Number of subjects: 80
Study 34582720 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg NEEM
Number of subjects: 80
Study 34582720 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg NEEM
Number of subjects: 80
Study 34582720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 33827081 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal High-Frequency Oscillatory Ventilation (NHFOV)
Number of subjects: 302
Study 33827081 — intervention group
Group type: COMPARATOR
Intervention: Nasal Continuous Airway Pressure (NCPAP)
Number of subjects: 302
Study 36424012 — intervention group
Group type: EXPERIMENTAL
Intervention: Conduction System Pacing (CSP)
Number of subjects: 70
Study 36424012 — intervention group
Group type: COMPARATOR
Intervention: Biventricular Pacing (BiVP)
Number of subjects: 70
Study 33597287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullying perpetration
Number of subjects: 28477
Study 33597287 — intervention group
Group type: COMPARATOR
Intervention: Combined bullying-victimization
Number of subjects: 28477
Study 32602592 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Evolutionary Therapy (CET)
Number of subjects: 97
Study 32602592 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Therapy (CT)
Number of subjects: 97
Study 34384777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of lower uterine segment thickness; those with measurements >3.5 mm encouraged to choose planned vaginal delivery, those with measurements ≤3.5 mm encouraged to choose planned repeat cesarean delivery.
Number of subjects: 2948
Study 34384777 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard management, no ultrasound measurement).
Number of subjects: 2948
Study 34384777 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of lower uterine segment thickness.
Number of subjects: 2948
Study 34384777 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard management).
Number of subjects: 2948
Study 32005226 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education on TB to HH contacts by HEWs
Number of subjects: 411
Study 32005226 — intervention group
Group type: EXPERIMENTAL
Intervention: Having TB treatment supporter (TTS) during intensive phase of index TB case
Number of subjects: 411
Study 32005226 — intervention group
Group type: EXPERIMENTAL
Intervention: HH visit by HEWs within 6 months prior to the programme assessment
Number of subjects: 411
Study 32005226 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussions about TB activities by HEWs with Women Development Army (WDA) leaders
Number of subjects: 411
Study 32117047 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral-lifestyle intervention (PEARS) supported by a smartphone app
Number of subjects: 565
Study 32117047 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 565
Study 36215222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod liver oil (5 mL/day, 10 µg of vitamin D, n=17,278)
Number of subjects: 34601
Study 36215222 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=17,323)
Number of subjects: 34601
Study 34155732 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular active dose of morphine (0.15 mg/kg)
Number of subjects: 0
Study 34155732 — intervention group
Group type: COMPARATOR
Intervention: Very low dose control (0.01 mg/kg)
Number of subjects: 0
Study 32878045 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined deep-sea water (RDSW)
Number of subjects: 98
Study 32878045 — intervention group
Group type: COMPARATOR
Intervention: Mineral water (control)
Number of subjects: 98
Study 35610013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianyi granules
Number of subjects: 361
Study 35610013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 33234053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ending Self‐Stigma intervention
Number of subjects: 248
Study 33234053 — intervention group
Group type: COMPARATOR
Intervention: Health and Wellness intervention
Number of subjects: 248
Study 32211679 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of mixed spices
Number of subjects: 13
Study 32211679 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of mixed spices
Number of subjects: 13
Study 32211679 — intervention group
Group type: COMPARATOR
Intervention: 0 g of mixed spices (no spices)
Number of subjects: 13
Study 33586502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine-specific stimuli
Number of subjects: 80
Study 33586502 — intervention group
Group type: COMPARATOR
Intervention: Neutral stimuli
Number of subjects: 80
Study 35135928 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA gait training
Number of subjects: 15
Study 35135928 — intervention group
Group type: COMPARATOR
Intervention: Control gait training
Number of subjects: 15
Study 33357089 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Training
Number of subjects: 80
Study 33357089 — intervention group
Group type: COMPARATOR
Intervention: Health Education
Number of subjects: 80
Study 33357089 — intervention group
Group type: COMPARATOR
Intervention: Wait-List
Number of subjects: 80
Study 36112258 — intervention group
Group type: EXPERIMENTAL
Intervention: Online visualization
Number of subjects: 146
Study 36112258 — intervention group
Group type: COMPARATOR
Intervention: Standard PrEP briefing
Number of subjects: 146
Study 34886058 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and DTC-GT (intervention group)
Number of subjects: 144
Study 34886058 — intervention group
Group type: COMPARATOR
Intervention: Health education (control group)
Number of subjects: 144
Study 34886058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study 35689178 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry and lung age announcement along with usual care
Number of subjects: 456
Study 35689178 — intervention group
Group type: COMPARATOR
Intervention: Standard program (control group)
Number of subjects: 456
Study 33211387 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffold (BVS) implantation
Number of subjects: 2070
Study 35953437 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE)
Number of subjects: 8179
Study 33530182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cervical traction combined with traditional Chinese medicine hot compress
Number of subjects: 100
Study 33530182 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cervical traction combined with hot compresses
Number of subjects: 100
Study 35005585 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation (2800 IU/day) during pregnancy
Number of subjects: 584
Study 35005585 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D sufficiency (≥ 75 nmol/l) at age 6 months
Number of subjects: 584
Study 35005585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D sufficiency at age 6 years
Number of subjects: 584
Study 35005585 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D supplementation during pregnancy with vitamin D sufficiency at age 6 years
Number of subjects: 584
Study 32293943 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pill (OCP)
Number of subjects: 9
Study 32293943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 33451738 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV2/2‐ND4 (single injection of 9 × 10^10 viral genomes in 90 μl)
Number of subjects: 38
Study 33451738 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 38
Study 32228690 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 2026
Study 32228690 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control)
Number of subjects: 2026
Study 35768939 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Start (ES) with Glatiramer Acetate (GA)
Number of subjects: 208
Study 33846735 — intervention group
Group type: COMPARATOR
Intervention: PAAPPAS-environment group (PEG)
Number of subjects: 2511
Study 33846735 — intervention group
Group type: COMPARATOR
Intervention: PAAPPAS group (PG)
Number of subjects: 2511
Study 36789634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (200/50 mg) under fasted conditions
Number of subjects: 72
Study 36789634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (200/50 mg) under fed conditions
Number of subjects: 72
Study 36789634 — intervention group
Group type: COMPARATOR
Intervention: Control (fasted state)
Number of subjects: 72
Study 36789634 — intervention group
Group type: COMPARATOR
Intervention: Control (fed state)
Number of subjects: 72
Study 33682060 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training in 20 °C (n=11)
Number of subjects: 21
Study 33682060 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise training in 33 °C (n=12)
Number of subjects: 21
Study 33682060 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training in 20 °C
Number of subjects: 21
Study 33682060 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise training in 33 °C
Number of subjects: 21
Study 32286507 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapy
Number of subjects: 0
Study 32286507 — intervention group
Group type: COMPARATOR
Intervention: Old therapy
Number of subjects: 0
Study 36127096 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and patient education
Number of subjects: 200
Study 36127096 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 34059094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) and ipilimumab (1 mg/kg every 6 weeks)
Number of subjects: 118
Study 34059094 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) and ipilimumab (1 mg/kg every 6 weeks) with UV1 vaccine (8 intradermal injections during the first three months)
Number of subjects: 118
Study 34059094 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab and ipilimumab
Number of subjects: 118
Study 36068002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional collagenase Clostridium histolyticum (CCH) injections
Number of subjects: 50
Study 36068002 — intervention group
Group type: COMPARATOR
Intervention: Intralesional verapamil (ILV) injections
Number of subjects: 50
Study 33479386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cissus Quadrangularis (CQ) extract
Number of subjects: 0
Study 33479386 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (PPAR-γ agonist)
Number of subjects: 0
Study 36013512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate 50 mg/kg
Number of subjects: 86
Study 36013512 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate 30 mg/kg
Number of subjects: 86
Study 32192467 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate syrup (1 cc/Kg containing 5 mg/5 cc zinc sulfate)
Number of subjects: 60
Study 32192467 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup (1 cc/Kg sucrose)
Number of subjects: 60
Study 35534904 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH VN intervention
Number of subjects: 350
Study 35534904 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 350
Study 33689524 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive randomization with adaptive clip method
Number of subjects: 0
Study 33689524 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility approach for randomization procedure selection
Number of subjects: 0
Study 35113046 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV-based ART
Number of subjects: 207
Study 35113046 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with PDR
Number of subjects: 207
Study 35113046 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants without PDR
Number of subjects: 207
Study 34462887 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-HL (high and low molecular weight hyaluronic acid formulation)
Number of subjects: 692
Study 34462887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study 34462887 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-HL
Number of subjects: 692
Study 35395276 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation (DE: 77Gy/35fx) to hypoxic volumes (HV)
Number of subjects: 53
Study 35395276 — intervention group
Group type: COMPARATOR
Intervention: Standard radiotherapy (ST: 70Gy/35fx)
Number of subjects: 53
Study 35395276 — intervention group
Group type: COMPARATOR
Intervention: Non-hypoxic tumors treated with standard radiotherapy (ST: 70Gy/35fx)
Number of subjects: 53
Study 34684481 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased protein intake to 1.7 g/kg body weight/d (New Zealand study, 10 weeks intervention)
Number of subjects: 148
Study 34684481 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased protein intake to 1.54 g/kg body weight/d (Austrian study, 6 weeks intervention)
Number of subjects: 148
Study 34684481 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal-based time effect observed in the Austrian study
Number of subjects: 148
Study 32386040 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial trigger point electroacupuncture therapy combined with solifenacin succinate
Number of subjects: 40
Study 32386040 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin succinate
Number of subjects: 40
Study 34236503 — intervention group
Group type: EXPERIMENTAL
Intervention: Array-RQMC
Number of subjects: 0
Study 34236503 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Monte Carlo
Number of subjects: 0
Study 32773226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (pitavastatin + ezetimibe)
Number of subjects: 880
Study 32773226 — intervention group
Group type: COMPARATOR
Intervention: Standard lipid-lowering therapy (pitavastatin monotherapy)
Number of subjects: 880
Study 35719228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Foam Rolling (VFR)
Number of subjects: 25
Study 35719228 — intervention group
Group type: EXPERIMENTAL
Intervention: Static Stretching (SS)
Number of subjects: 25
Study 35719228 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 25
Study 34312204 — intervention group
Group type: EXPERIMENTAL
Intervention: StandingTall programme
Number of subjects: 400
Study 32212801 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg once daily for at least 7 days
Number of subjects: 49
Study 32212801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tab once daily for at least 7 days)
Number of subjects: 49
Study 33410912 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 197
Study 33410912 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 197
Study 34687635 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily or 2.5 mg twice daily)
Number of subjects: 101
Study 34687635 — intervention group
Group type: COMPARATOR
Intervention: Avoid anticoagulation (oral antiplatelet agents could be prescribed)
Number of subjects: 101
Study 36475824 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Assertive Community Treatment (FACT)
Number of subjects: 131
Study 36475824 — intervention group
Group type: COMPARATOR
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 131
Study 33595776 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0
Study 33595776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32150649 — intervention group
Group type: EXPERIMENTAL
Intervention: CMD (chlorambucil, mitoxantrone and dexamethasone)
Number of subjects: 400
Study 32150649 — intervention group
Group type: COMPARATOR
Intervention: FMD (fludarabine, mitoxantrone and dexamethasone)
Number of subjects: 400
Study 32150649 — intervention group
Group type: EXPERIMENTAL
Intervention: CMD
Number of subjects: 400
Study 32150649 — intervention group
Group type: COMPARATOR
Intervention: FMD
Number of subjects: 400
Study 32150649 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular negativity (both CMD and FMD)
Number of subjects: 400
Study 32150649 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD negative patients (both CMD and FMD)
Number of subjects: 400
Study 36163929 — intervention group
Group type: EXPERIMENTAL
Intervention: Asciminib 80mg once daily (QD)
Number of subjects: 69
Study 36163929 — intervention group
Group type: COMPARATOR
Intervention: Investigator-selected TKI (imatinib, bosutinib, dasatinib, or nilotinib at their approved doses)
Number of subjects: 69
Study 33604379 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram incorporating Rad-score and clinical risk factors
Number of subjects: 80
Study 33604379 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 80
Study 36192125 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique (EFT) in military intervention group
Number of subjects: 133
Study 36192125 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Freedom Technique (EFT) in nonmilitary intervention group
Number of subjects: 133
Study 36192125 — intervention group
Group type: COMPARATOR
Intervention: Military control group
Number of subjects: 133
Study 36192125 — intervention group
Group type: COMPARATOR
Intervention: Nonmilitary control group
Number of subjects: 133
Study 32764089 — intervention group
Group type: EXPERIMENTAL
Intervention: High schools High on life intervention
Number of subjects: 16
Study 34039560 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual subretinal fluid (SRF) at month 3
Number of subjects: 785
Study 34039560 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual SRF of any thickness (>0-50 μm, >50-100 μm, >100 μm)
Number of subjects: 785
Study 34039560 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-resistant subretinal fluid (TR-SRF)
Number of subjects: 785
Study 34039560 — intervention group
Group type: COMPARATOR
Intervention: No residual SRF
Number of subjects: 785
Study 33414066 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient hospitalisation
Number of subjects: 160
Study 33414066 — intervention group
Group type: COMPARATOR
Intervention: Inpatient hospitalisation
Number of subjects: 160
Study 34032505 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (41 subjects)
Number of subjects: 80
Study 34032505 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (39 subjects)
Number of subjects: 80
Study 34405742 — intervention group
Group type: EXPERIMENTAL
Intervention: P044
Number of subjects: 66
Study 34405742 — intervention group
Group type: COMPARATOR
Intervention: Forsteo®
Number of subjects: 66
Study 33887244 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIS plus GBT
Number of subjects: 336
Study 35641862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin oral administration (500 mg) in morbidly obese individuals (n=10)
Number of subjects: 28
Study 35641862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin intravenous administration (400 mg) in morbidly obese individuals (n=10)
Number of subjects: 28
Study 35641862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin oral (500 mg) followed by intravenous (400 mg) administration in non-obese individuals (n=8)
Number of subjects: 28
Study 35641862 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin pharmacokinetics in obese individuals
Number of subjects: 28
Study 34663404 — intervention group
Group type: EXPERIMENTAL
Intervention: Avapritinib (selective kinase inhibitor); administered daily
Number of subjects: 38
Study 32253046 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention provided to participants
Number of subjects: 156
Study 32253046 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 156